Biotech Startups

PhenoTap develops KetoTap Core, a patent-pending BHB oxidase enzyme designed for reliable, affordable, real-time ketone measurement in blood test strips and continuous monitors. It offers the enzyme as a drop-in technology for device makers building glucose-style sensors, targeting continuous ketone monitoring for health and therapeutic applications.

1 investor

Pheromite develops solutions to help beekeepers combat the varroa mite, using molecular target research and drug design methods such as in silico screening. It serves commercial and hobbyist beekeepers and is based in Auckland, New Zealand.

1 investor

Phicrobe develops rapid diagnostic tests for detecting E. coli O157:H7 using genetically modified bacteriophage technology that produces light in the presence of the pathogen. The technology enables pathogen detection without specialized equipment or expensive reagents for use in food safety and clinical testing applications.

1 investor

Philogen discovers and develops targeted anti-cancer biopharmaceutical drugs using monoclonal antibodies and small molecules for tumor-specific delivery. The company focuses on vascular targeting to deliver therapeutic agents to tumors while sparing healthy tissues.

1 investor

Phinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.

1 investor

Phoenix PharmaLabs is a pharmaceutical company that welcomes inquiries from organizations seeking business relationships and potential opportunities.

1 investor

Phoenix SENOLYTIX develops gene therapies targeting senescent cells to address aging-related conditions. The company utilizes its ApoptiCIDe-CE™ platform technology, validated in human patients, to eliminate unwanted cells in the body.

1 investor

Advanced wound care dressing made from a patented nanocomposite carbon-polymer.

1 investor

PhorMed develops next-generation therapies targeting inflammation-driven diseases, particularly rare oncological conditions, using AI-powered targeting technology. The company serves patients with inflammatory and cancer-related diseases, focusing on improving efficacy and safety of first-line treatments.

1 investor

Phosphoenix is developing a neuroprosthetic system that restores functional vision in people with profound blindness by directly stimulating the brain's visual pathway, targeting the lateral geniculate nucleus. Its core technology is a high-density, ultra-flexible neural interface for precise deep-brain stimulation.

1 investor

PhotonPharma develops riboflavin and UV-based treatment technology (disposables and equipment) optimized for cancer immunotherapy and vaccine production. The company works with Colorado State University's School of Biomedical Engineering and external consultants to advance its immunotherapy platform.

1 investor

PhotoQ3 is a research and development company developing gentle treatment methods for diseases that currently lack cures. Its stated mission is to contribute to patients and society through these therapies.

1 investor

PhyCo is a marine biotechnology company producing compostable, seaweed-based bioplastics as alternatives to petroleum plastics used in agriculture and food supply systems. Working with native Canadian seaweed species and in partnership with Indigenous Nations, it targets plastic used in farming operations across Canada.

1 investor

Phyla produces skincare products for acne-prone skin, including a pH-balancing gel cleanser that removes excess oil without irritation. The company focuses on microbiome-conscious formulations recommended by dermatologists.

1 investor

Phyllome grows edible plants engineered to express cyclotide therapeutic peptides, turning them into functional foods with controlled therapeutic dosing as an oral alternative to injected or synthetic drugs. Its pipeline targets analgesic, cholesterol-modulating, and appetite-regulating applications, developed with the University of Queensland's Institute for Molecular Bioscience.

1 investor

Physiomics is a consultancy that applies mathematical modelling and biostatistics to support drug development and clinical trials for pharmaceutical and biotech clients.

1 investor

PhytoGenesis develops PreviSAR, an mRNA-based biological crop protection product that activates a plant's own Systemic Acquired Resistance as a non-toxic alternative to chemical pesticides for farmers. The company operates in the agtech sector, building on University of Kentucky research.

1 investor

Phytonix is an industrial biotechnology company that uses genetically engineered cyanobacteria and synthetic biology to convert carbon dioxide emissions and sunlight into sustainable chemicals and fuels, starting with n-butanol as a drop-in gasoline replacement and industrial chemical. It targets the global n-butanol chemical market and co-locates its production with industrial CO2 emitters.

1 investor

Piatrika Biosystems builds genomics and AI-driven software for agriculture, serving seed and agricultural input companies to support molecular breeding, regulatory compliance, and crop development. The company operates R&D and technology teams in Cambridge, U.K. and Hyderabad, India.

1 investor

1 investor

Picket Pharmaceuticals uses AI/ML data analytics to identify supply shortages and undervalued generic drug opportunities in the pharmaceutical market, then acquires or licenses these overlooked products through its industry network.

1 investor

PicnicAI applies AI to care delivery and clinical research, offering patient-facing tools that unify a person's medical records across providers and AI-driven services that speed up and reduce the cost of drug development. It serves patients seeking to navigate fragmented care and the clinical research and pharmaceutical sector.

1 investor

Picodya develops microfluidic diagnostic technology designed to increase access to diagnostic testing worldwide. The company applies its pico technology platform to enable faster, more efficient medical diagnostics for global populations.

1 investor

1 investor